engleski

The potential use of selected polyphenols in treatment of polycythemia vera and essential thrombocytosis

Introduction: Polycythemia vera (PV) and essential thrombocytosis/thrombocythemia (ET) are the most common myeloproliferative diseases. Still, their treatment is almost exclusively symptomatic since molecular targets for the treatment of these diseases have been recognized only recently. Some polyphenolic compounds are known antagonists of these molecular targets and as such they represent good candidates for treatment of PV and ET. Materials and methods: This study is based on the literature search for polyphenols that posses antagonistic effects against molecular targets for treatment of PV and ET. Results: At least four widely available polyphenols, namely quercetin, luteolin, genistein and epigallocatechin-3-gallate (EGCG) have been found to attenuate the effects of EGFR, FLT3 or Aurora kinases which are potential molecular targets for PV and ET therapy. All of these compounds attenuate EGFR effects while two of them are also inhibitors of FLT3 and Aurora kinases. It seems that none of these polyphenols inhibits JAK2 kinase, the primary therapeutic target for PV and ET but at least five less common polyphenols posses this property. Amidst these apigenin represents the most interesting compound since it can inhibit JAK2 kinase and it simultaneously antagonize effects of EGFR activation. Conclusions: Quercetin, luteolin, EGCG and apigenin stand out among studied polyphenolic compounds since they antagonize actions of two or more molecular targets for treatment of PV and ET. Therefore they represent promising candidate compounds for causal treatment of these diseases.

polyphenols; polycthemia vera; essential thrombocytosis

nije evidentirano